TP53 and hepatocellular carcinoma: These findings were in line with a previous work by Torrecilla S. et al. [114] where they described TERT, TP53, and CTNNB1 mutations as trunk alterations in HCC, meaning they are ubiquitously present across different regions of the same tumor and between primary and metastatic tumors in more than 85% of the cases studied.